Ebenbuild Secures €2.3 Million EIC Grant to Advance Digital Twin Platform for Respiratory Drug Development
核心洞察
Ebenbuild (搜索) received €2.3 million from the European Innovation Council (搜索) Accelerator program to advance its AI-enabled digital twin platform for lung simulation and respiratory drug development.
The funding supports the market launch of Twinhale (搜索), the first scalable in silico trial software for pulmonary drug delivery that enables patient-specific predictions of drug deposition in lungs.
Validation studies demonstrate Twinhale (搜索)'s unprecedented accuracy in predicting local drug deposition, outperforming existing models and enabling design decisions typically inaccessible through traditional testing methods.
Munich-based digital health company Ebenbuild (搜索) has secured €2.3 million in funding from the European Innovation Council (搜索) (EIC) Accelerator program to advance its AI-enabled digital twin platform for respiratory health applications. The EIC fund will also invest up to €10 million in future equity financing rounds, providing significant validation from one of Europe's most competitive technology funding programs.
The funding will support the market launch of Twinhale (搜索), described as the first scalable simulation tool that enables physiologically accurate, patient-specific predictions of drug deposition in the lungs. Built on Ebenbuild (搜索)'s proprietary technology platform, Twinhale offers pharmaceutical and medtech companies a cost-efficient approach to digitally simulate pulmonary drug delivery, potentially reducing trial failure rates, costs, and time-to-market.
Validation Studies Demonstrate Superior Accuracy
Ebenbuild (搜索) has already applied its Twinhale (搜索) software in pilot studies with PARI Pharma (搜索) and Pieris Pharmaceuticals. In validation studies, Twinhale predicted local drug deposition with unprecedented accuracy, outperforming existing models and enabling design decisions that are typically inaccessible through in vivo or in vitro testing.
"With Twinhale (搜索), we are not only reducing attrition rates in respiratory drug development – we are also generating first-of-its-kind datasets that can drive regulatory acceptance and unlock companion diagnostic strategies in the future," said Dr. Maximilian Grill, Head of In Silico Trials at Ebenbuild (搜索).
Targeting Expanding Digital Health Markets
The company operates in a rapidly growing €5 billion in silico trials market and is positioning itself to enter the clinical decision support systems (CDSS) and personalized medicine markets, collectively estimated at over €300 billion by 2030. Backed by HTGF (搜索), Bayern Kapital (搜索) and angel investors, Ebenbuild (搜索)'s platform technology aims to deepen understanding of respiratory diseases and individual pathophysiology.
"Our vision is to become the leading health intelligence platform for respiratory diseases," said Dr. Kei Müller, CEO and Co-founder of Ebenbuild (搜索). "Twinhale (搜索) is just the beginning. The very same core platform will power future regulated products for mechanical ventilation optimization and chronic respiratory disease management."
Expanding Platform Applications
The company's long-term roadmap spans from preclinical simulations to clinical-grade decision support systems. As a follow-up product, Ebenbuild (搜索) is developing software for optimizing mechanical ventilation in patients with lung complications – a €10 billion market segment with strong clinical demand, rapid feedback cycles, and clear economic benefits.
Ebenbuild (搜索)'s digital toolset combines physics-based simulation, artificial intelligence, and data science to support decision makers in the life sciences and healthcare industries. The platform enables products ranging from personalized decision support to improve patient outcomes in severe respiratory diseases to in silico trials designed to accelerate and de-risk the development of inhaled drugs.